Advancing Healthcare through Science & Innovation
AstraZeneca is a global, science-led, patient-focused biopharmaceutical company that develops, manufactures and markets revolutionary treatments and biopharmaceuticals to address a wide range of diseases and medical conditions. Its areas of focus are oncology, chronic diseases, rare diseases, biopharmaceuticals and vaccines.
One of AstraZeneca’s major achievements is the development and launch of AZD1222 vaccines which played a critical role in addressing the Covid-19 pandemic. It became the most widely used vaccine in the world. In Indonesia, 107.4 million doses were delivered which helped prevent 93,954 deaths.
Later renamed Vaxzevria, the vaccine saved more than six million lives worldwide in the first year. AstraZeneca’s Evusheld, with its long-acting combination of antibodies, continues to help protect those most vulnerable to COVID-19.
What puts AstraZeneca at the Top
AstraZeneca Indonesia is the number one MNC Pharmaceutical Company in Indonesia according to IQVIA Market Data 2022. Its success is due to its ability to continually deliver life-changing and innovative medicines in the region, contributing significantly to the advancement in healthcare. There are additional factors and they are:
Scientific Leadership and Innovation: The company’s focus in science and innovation include developing the next generation of therapeutics through advanced biologics, nucleotide-based drugs and cell therapies, and converging science, data and technology to develop breakthrough medicines to address the growing burden of disease.
Sustainability and Social Responsibility: The company operates sustainably as it recognises the interconnectedness between business growth, societal needs, and environmental considerations. AstraZeneca actively invests resources to create both financial and non-financial value that benefits patients, society, and its business.
AstraZeneca’s 5R Framework: AstraZeneca’s drug discovery and development is guided by their 5R Framework which champions quality over quantity, and has helped transform the culture of R&D and their business. In the last decade, they achieved an almost six-fold improvement in the proportion of pipeline molecules from 4% to 23%. This improvement moves them well above the current industry average success rate of 14% in the 2018-2020 timeframe.
Strong Manufacturing and Commercialization Capabilities: AstraZeneca’s capabilities in research, development, manufacturing, and commercialization of medicines as well as its ability to bring medicines to market efficiently and effectively reinforces its position in the region. In 2022, AstraZeneca’s total revenue increased by 19% to $44.4bn from product sales of their existing medicines and new medicine launches, as well as from their collaboration activities. This success demonstrates that they are on track to deliver industry leading revenue growth through 2025 and beyond.
Track Record of Launching New Medicines: AstraZeneca has launched 20 new medicines in the last 10 years, including three in 2022 alone.
Blockbuster Medicines and Market Approvals: With 14 blockbuster medicines generating annual revenues exceeding $1 billion and a record 34 approvals of medicines in major markets in 2022, AstraZeneca’s financial success and market acceptance in Asia are undeniable.
Leadership in Fighting the COVID-19 Pandemic: AstraZeneca’s commitment to support the global fight against COVID-19 includes providing millions of COVID-19 vaccines at no profit in Indonesia during the worst stages of the pandemic. In addition to saving millions of lives, these COVID-19 vaccinations also saved an estimated US$8.1b in pandemic healthcare costs in Indonesia.
AstraZeneca’s People: In 2022, AstraZeneca empowered 83,500 employees in a dynamic, inclusive, and high-performing environment, including in Indonesia. They focused on coaching, development, and employee contribution and conducted 555 performance development workshops for 16,500 participants. The company also provided continuous recognition, giving 269,000 rewards to 68% of employees, with 20% being cross-functional. Women make up 52.9% (approximately 43,900) of their global workforce, and their Board comprises five women (38% of the total). An internal survey showed that 83% of AstraZeneca employees felt comfortable speaking up and expressing their opinions at work.
